7 Best Peptides for Cirrhosis

What to Know Before Choosing a Peptide for Cirrhosis

Cirrhosis is scar tissue that has replaced healthy liver cells over time, and the medical consensus on advanced cases is sobering: established cirrhosis cannot currently be reversed by any approved agent. Early or compensated cirrhosis, where the liver has not yet lost its functional reserve, may respond differently, with genuine regenerative potential remaining. That distinction matters a great deal for understanding what any compound can realistically offer.

A peptide earns a slot on this list because people use it for liver cirrhosis or are actively discussing it in that context, not because it holds FDA approval or has deep randomized-trial support. FDA-approved drugs, telemedicine-accessible compounds, and research-only peptides are all included. Where the evidence is thin, that fact is stated plainly inside the entry itself. Where a compound has only community-reported use and no published human trial data, that is described honestly rather than used as a reason to leave the compound off a list that is supposed to reflect what people actually reach for.

The entries below are ordered by how prominently each compound appears across published research and in real-world use, not as a verdict on which is best for any individual. One important caution applies across every entry: liver disease changes how the body processes compounds, and decompensated cirrhosis, the stage marked by ascites, bleeding risk, or encephalopathy, carries meaningful additional risks for nearly every class of treatment discussed here. Nothing in this article substitutes for guidance from a clinician who knows your liver function numbers and your full history.

1. GLP-1 Receptor Agonists: The Most Clinically Advanced Peptide Class

GLP-1 receptor agonists are peptide-based drugs originally developed for type 2 diabetes and obesity that have become the most clinically studied peptide class for liver disease. Semaglutide, tirzepatide, and liraglutide all belong here, and their evidence base in liver fibrosis and metabolic liver disease is now the strongest available for any peptide class in human beings.

Semaglutide received FDA accelerated approval in August 2025 for metabolic dysfunction-associated steatohepatitis with liver fibrosis at stages F2 through F3. In a phase 3 randomized controlled trial involving more than 1,100 participants, 62.9 percent achieved MASH resolution and 36.8 percent showed measurable fibrosis improvement. Tirzepatide, a dual GLP-1 and GIP receptor agonist, showed even stronger signals in phase 2, with 73.3 percent MASH resolution and 54.2 percent fibrosis improvement at its highest dose in a study published in the New England Journal of Medicine, with phase 3 data ongoing.

There is a critical limitation every person researching this topic needs to understand clearly. Both approvals and pivotal trials enrolled patients with fibrosis at stages F2 and F3, which are advanced fibrosis but not yet cirrhosis. Patients with established cirrhosis at stage F4 were explicitly excluded from the semaglutide approval. In people with compensated cirrhosis, GLP-1 agonists appear generally safe and are used off-label under physician supervision, with clinical guidelines characterizing their safety profile as acceptable for that group. In decompensated cirrhosis the picture changes significantly: these drugs are not recommended and should be discontinued if decompensation develops, partly because of the risk of accelerating muscle loss in patients who are already nutritionally fragile.

GLP-1 agonists work in part by regulating appetite and energy metabolism at the level of the hypothalamus and gut, reducing the fat accumulation and inflammatory stress that drive hepatic stellate cell activation and fibrosis progression. There is also growing real-world interest in their effect on alcohol cravings, with users reporting reduced or eliminated urges to drink. For people whose cirrhosis is rooted in alcohol-related liver disease, that behavioral signal, while not the primary therapeutic mechanism, carries indirect significance.

The most common adverse effects are gastrointestinal, primarily nausea during dose escalation, diarrhea, and occasional vomiting. Rare but serious risks include pancreatitis and gallbladder complications. Anyone with a personal or family history of medullary thyroid cancer should not use this class of drug.

2. BPC-157: The Most Researched Peptide for Liver Fibrosis in Animal Models

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice, and it is the most discussed research peptide for liver repair in biohacking and peptide communities. Its mechanism in liver tissue is unusually specific for a research compound, targeting several of the molecular processes that drive fibrosis directly.

In preclinical models, BPC-157 suppresses TGF-beta-1, the signaling protein that sits near the top of the fibrosis cascade and drives hepatic stellate cells, the primary scar-producing cells in the liver, to proliferate and lay down collagen. It also disrupts the FAK-paxillin interaction, a structural handshake between proteins that keeps stellate cells locked in their scar-producing state. On the other side of the equation, it increases MMP-13, a collagenase enzyme that breaks down existing scar matrix, while reducing TIMP-1, the inhibitor that normally keeps that enzyme switched off. The combined effect in animal studies is a shift toward matrix degradation rather than accumulation. Prevention of liver necrosis has also been demonstrated in rat models.

To be direct about what the evidence is not: no human clinical trial has been published for BPC-157 in liver cirrhosis or liver fibrosis as of 2026. Every mechanism described above comes from preclinical models, primarily rats. The translation to human liver disease has not been established in controlled research.

Community use tells a different story in terms of how widely this compound is discussed. Across Reddit and biohacking forums, BPC-157 is the most frequently mentioned research peptide for liver repair. An analysis of more than 1,200 BPC-157 user reports found that the majority described soft tissue healing benefits, with liver-specific use representing a subset of that pattern. One widely shared anecdotal account involved a user claiming complete cirrhosis resolution after cycling BPC-157 with another peptide over several years, though no laboratory data accompanied the claim and the exact diagnosis was uncertain. That kind of report is included here because it reflects what people in this community are talking about and acting on, not because it constitutes evidence of efficacy.

Purity matters significantly with BPC-157. A subset of users in community reports experienced worsening inflammation from batches with bacterial contamination. For anyone with compromised liver function, that risk carries added weight, since the liver is both the primary site of the hoped-for benefit and the organ handling whatever enters the body.

3. Aldafermin: The Only Peptide Tested in a Human Trial Specifically for Cirrhosis

Aldafermin is an analog of fibroblast growth factor 21, a naturally occurring metabolic hormone, and it holds a distinction that no other peptide on this list can claim: it has been tested in a randomized, double-blind, placebo-controlled human trial specifically enrolling patients with compensated NASH cirrhosis.

In that trial, published in a peer-reviewed hepatology journal, aldafermin produced a statistically significant reduction in Enhanced Liver Fibrosis scores at 48 weeks, with a mean difference of 0.5 points compared to placebo. The ELF score is a validated non-invasive marker of fibrosis severity, so a reduction at the treatment group level reflects real biological change in the liver's connective tissue burden. That number is modest in absolute terms, but the study design and population make it meaningful: this is controlled human evidence of fibrosis movement in actual cirrhotic patients, which the rest of the peptide field has largely failed to produce.

Aldafermin is not FDA-approved for any indication and is not available through standard commercial channels. It exists in the research pipeline and is accessed only through clinical trial participation. It works through FGF21 receptor signaling to reduce liver fat, inflammation, and downstream fibrosis, representing a distinct pathway from the GLP-1 drugs and research peptides that dominate most lists on this topic.

For people researching this topic who are living with cirrhosis and looking for options, aldafermin is worth knowing about not as something to obtain independently, but as a signal that human trial-level investigation of cirrhosis-specific fibrosis is actively underway and producing early positive results.

4. TB-500: The Community Companion to BPC-157

TB-500 is a synthetic analog of thymosin beta-4, a naturally occurring peptide involved in cell repair, tissue remodeling, and the regulation of actin, the structural protein that gives cells their shape and allows them to migrate toward sites of injury. It is rarely discussed in isolation in the cirrhosis community. Nearly every community reference to BPC-157 in a liver repair context eventually mentions TB-500 as a cycling partner, and that consistent pattern of co-use is exactly why it belongs on this list.

Thymosin beta-4 has been studied across a range of liver injury models in animals, including alcohol-induced liver disease, ischemia-reperfusion injury, and fibrosis models, with anti-inflammatory and tissue-repair signals appearing across all of them. A phase 1 trial of recombinant thymosin beta-4 in healthy adults found no serious adverse events and no liver toxicity, though that population is meaningfully different from someone with existing cirrhosis.

No human clinical trial data exists for TB-500 in liver cirrhosis as of 2026. What drives its inclusion here is not a clinical evidence base but the consistency of its presence in community protocols for liver repair, particularly in combination with BPC-157. Community use and discussion for this goal are the inclusion criterion this list applies, and TB-500 meets it clearly.

One uncertainty worth stating plainly: the long-term safety profile of TB-500 in people with compromised liver function is unknown. The liver metabolizes and clears many compounds, and a damaged liver does that job less efficiently. That gap in the safety picture should factor into any conversation with a clinician about whether this compound belongs in a given individual's situation.

5. GHK-Cu: Antioxidant and Matrix Remodeling Signal

GHK-Cu is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. It has attracted research interest in liver disease through a mechanism that partially overlaps with BPC-157 while approaching fibrosis from a different angle.

In mouse models of NASH and liver fibrosis, GHK-Cu reduces TGF-beta-1 levels, the same upstream fibrosis driver that BPC-157 targets, and it also activates the Nrf2 pathway, a master regulator of the cell's antioxidant response. Think of Nrf2 as the cell's internal damage-control switch: when it is turned on, the cell ramps up production of protective enzymes that neutralize the oxidative stress driving hepatocyte death and stellate cell activation in chronically inflamed liver tissue. GHK-Cu also modulates matrix metalloproteinase activity, contributing to the extracellular matrix remodeling picture alongside those antioxidant effects.

No human clinical trial data has been published for GHK-Cu in liver cirrhosis or fibrosis as of 2026. The evidence is entirely preclinical, conducted in mouse models. Its appearance in peptide community discussions about liver health is more modest than BPC-157 or TB-500, but it is present, and the mechanistic rationale in animal data is specific enough to the liver fibrosis biology to make it a compound people researching this topic will encounter.

GHK-Cu is primarily known in the cosmetics and skin biology space, where it is used topically for collagen support and wound healing. Its application in a liver fibrosis context represents a different use case with a different delivery consideration, and that distinction matters when evaluating community protocols that reference it.

6. Ovagen: Liver-Specific Peptide Bioregulator

Ovagen belongs to a class of compounds called peptide bioregulators, developed primarily by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The theory behind this class is that very short peptide sequences, typically two to four amino acids in length, act as tissue-specific gene regulators, entering cell nuclei and influencing the expression of genes in the organ from which they are derived. Ovagen is specifically positioned as a liver bioregulator, with its short peptide sequences sourced from liver tissue and claimed to support hepatocyte function, detoxification pathways, and cellular regeneration.

The evidence for Ovagen in mainstream Western scientific literature is extremely limited. Research on peptide bioregulators as a class has been published, primarily in Russian and Eastern European journals by the Khavinson group, but these studies have not been replicated in large-scale randomized controlled trials in Western peer-reviewed databases, and cirrhosis-specific data is not available in the sources reviewed for this article. What places Ovagen here is its active presence in biohacking and longevity communities and in Eastern European supplement and clinical traditions, where it is used as part of organ-support protocols. The evidence here is experiential rather than clinical, and that distinction is important for anyone weighing their options.

Ovagen is typically taken as an oral capsule and sold as a dietary supplement in various countries, putting it in a different regulatory and accessibility category than injectable research peptides. It is not FDA-approved as a drug. People using it for liver support do so on the basis of the bioregulator framework and supplement-tier evidence, not on the basis of controlled human trial data.

7. Svetinorm: The Liver Bioregulator Often Paired with Ovagen

Svetinorm occupies almost exactly the same category as Ovagen in terms of its origin, mechanism theory, evidence base, and community use. It is also a peptide bioregulator from the Khavinson research tradition, marketed as a liver-specific compound derived from hepatic tissue, and used in Eastern European longevity and functional medicine circles as a hepatoprotective supplement.

The distinction between Ovagen and Svetinorm in the available literature is not always sharply defined. Some sources treat them as interchangeable liver bioregulators; others describe Svetinorm as more specifically targeted at hepatocyte normalization and oxidative stress reduction, with claimed support for ALT and AST normalization, the liver enzyme markers that clinicians use to track hepatic inflammation. In practice, they are often used together or in alternating cycles within bioregulator protocols rather than as standalone choices.

No published randomized controlled trial data exists for Svetinorm in liver cirrhosis as of 2026, and independent peer-reviewed evidence in Western scientific databases is essentially absent. The evidence base is the same as Ovagen's: primarily theoretical, grounded in the peptide bioregulator framework, with real-world use in communities that have adopted that model. People who discuss Svetinorm in the context of cirrhosis are generally doing so as part of a broader bioregulator protocol rather than pointing to a specific clinical result.

Svetinorm is sold as an oral supplement, is not FDA-approved, and its safety in decompensated cirrhosis has not been studied. Its inclusion here reflects the reality that it is discussed and used for liver support in the communities this article serves, with the honest acknowledgment that the evidence base is thin and the mechanistic claims remain largely theoretical.

How These Peptides Compare

Frequently Asked Questions

Can peptides reverse established cirrhosis?

No peptide has been shown to reverse established cirrhosis in human clinical trials. Advanced cirrhosis involves structural scar tissue replacing functional liver cells, and that architectural change is not currently reversible by any approved compound. Early or compensated cirrhosis retains more regenerative potential, which is why some of the compounds discussed here have been studied in that population specifically. The honest framing for every option on this list is harm reduction, fibrosis slowdown, and support for remaining liver function, not reversal of established disease.

Are any of these peptides legally available for liver disease?

GLP-1 receptor agonists like semaglutide are FDA-approved drugs available by prescription, though use in cirrhosis is off-label since the approval covers non-cirrhotic fibrosis stages. Aldafermin is accessible only through clinical trial participation. BPC-157, TB-500, and GHK-Cu are classified as research chemicals in most jurisdictions and are not approved for human therapeutic use, though they are available through research chemical suppliers and sometimes via physician-supervised compounding. Ovagen and Svetinorm are sold as dietary supplements in various countries. The legal picture varies by country and changes over time, so verifying current status in your jurisdiction is important.

Is it safe to use research peptides when you already have liver disease?

Liver disease significantly changes how the body processes and clears compounds, and that shift applies to research peptides as much as to approved drugs. Decompensated cirrhosis, the stage involving complications like fluid accumulation, bleeding risk, and cognitive changes, is a particularly high-risk context for any unmonitored compound. Even in compensated cirrhosis, the safety of research peptides like BPC-157 and TB-500 in patients with liver disease specifically has not been studied in controlled settings. Anyone with cirrhosis considering any compound on this list should do so with a clinician who can monitor liver function markers before and during use.

Why do semaglutide and tirzepatide not apply to cirrhosis patients?

The clinical trials that produced the phase 3 data for semaglutide and the phase 2 data for tirzepatide in liver disease enrolled patients with fibrosis at stages F2 and F3, which are advanced fibrosis but not yet cirrhosis. Patients with established cirrhosis at stage F4 were excluded from those trials by design, meaning the evidence of benefit does not extend to that population. In decompensated cirrhosis, GLP-1 drugs carry a specific risk of accelerating muscle loss in patients who are already nutritionally fragile, which is why guidelines advise discontinuing them if decompensation occurs.

How do people in the peptide community typically use BPC-157 for liver support?

In community protocols, BPC-157 for liver support is almost always discussed as an injectable compound rather than an oral one, on the basis that injectable delivery is generally considered more bioavailable. It is frequently cycled alongside TB-500. Community reports consistently emphasize purity as a critical variable, with a subset of users reporting adverse inflammatory reactions from batches with bacterial contamination. For someone with compromised liver function, sourcing and purity are not minor considerations. The broader point is that community use patterns are not the same as clinical protocols, and the liver-specific evidence behind these community practices remains entirely preclinical.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and real-world use of peptides for cirrhosis in one place.